Synthesis and biological activity of 5-{4-[2-(Methyl-p-substituted phenylamino)ethoxy]benzyl}thiazolidine-2,4-diones

Archives of Pharmacal Research

Volumn 30, Issue 9, 2007, Pages 1055-1061

  Hyo, Jin Gim ^a   Kang, BoMi ^a   Jeon, Raok ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Diabetes; Inflammation; Nitric oxide; PPAR ; Thiazolidinedione

Indexed keywords

EID: 34848902890     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02980237     Document Type: Article

References (21)

1. Alleva, D. G., Johnson, E. B., Lio, F. M., Boehme, S. A., Conlon, P. J., and Crowe, P. D., Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J. Leukoc. Biol., 71, 677-685 (2002).
2. Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611 (2000).
3. Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Annu. Rev. Med., 53, 409-435 (2002).
4. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Smith, S. A., and Thurlby, P. L., [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994).
5. Colville-Nash, P. R., Qureshi, S. S., Willis, D., and Willoughby, D. A., Inhibition of inducible nitric oxide synthase by peroxisome proliferator- activated receptor agonists: correlation with induction of heme oxygenase 1. J. Immunol., 161, 978-984 (1998).
6. Crosby, M. B., Svenson, J., Gilkeson, G. S., and Nowling, T. K., A novel PPAR response element in the murine iNOS promoter. Mol. Immunol., 42, 1303-1310 (2005).
7. Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20, 649-688 (1999).
8. Dobashi, K., Asayama, K., Nakane, T., Kodera, K., Hayashibe, H., and Nakazawa, S., Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. Life Sci., 67, 2093-2101 (2000).
9. Heneka, M. T., Feinstein, D. L., Galea, E., Gleichmann, M., Wullner, U., and Klockgether, T., Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol., 100, 156-168 (1999).
10. Henke, B. R., Blanchard, S. G., Brackeen, M. F., Brown, K. K., Cobb, J. E., Collins, J. L., Harrington, W. W., Jr., Hashim, M. A., Hull-Ryde, E. A., Kaldor, I., Kliewer, S. A., Lake, D. H., Leesnitzer, L. M., Lehmann, J. M., Lenhard, J. M., Orband-Miller, L. A., Miller, J. F., Mook, R. A., Jr., Noble, S. A., Oliver, W., Jr., Parks, D. J., Plunket, K. D., Szewczyk, J. R., and Willson, T. M., N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem., 41, 5020-5036 (1998).
11. Green, L. C., Wagner, D. A., Glogowski, J., Skipper, P. L., Wishnok, J. S., and Tannenbaum, S. R., Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem., 126, 131-138 (1982).
12. Ibrahimi, A., Teboul, L., Gaillard, D., Amri, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimaldi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070-1076 (1994).
13. Jiang, C., Ting, A. T., and Seed, B., PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 391, 82-86 (1998).
14. Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease. Nature, 405, 421-424 (2000).
15. Kletzien, R. F., Clarke, S. D., and Ulrich, R. G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398 (1992).
16. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995).
17. Lohray, B. B., Bhushan, V., Rao, B. P., Madhavan, G. R., Murali, N., Rao, K. N., Reddy, A. K., Rajesh, B. M., Reddy, P. G., Chakrabarti, R., Vikramadithyan, R. K., Rajagopalan, R., Mamidi, R. N., Jajoo, H. K., and Subramaniam, S., Novel euglycemic and hypolipidemic agents. 1. J. Med. Chem., 41, 1619-1630 (1998).
18. Oguchi, M., Wada, K., Honma, H., Tanaka, A., Kaneko, T., Sakakibara, S., Ohsumi, J., Serizawa, N., Fujiwara, T., Horikoshi, H., and Fujita, T., Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. J. Med. Chem., 43, 3052-3066 (2000).
19. Reilly, C. M., Oates, J. C., Cook, J. A., Morrow, J. D., Halushka, P. V.,and Gilkeson, G. S., Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J. Immunol., 164, 1498-1504 (2000).
20. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 391, 79-82 (1998).
21. Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung, 40, 37-42 (1990).